Skye Bioscience, Inc. earnings releases SKYE

Annual Quarterly

Skye Bioscience, Inc. last reported quarterly results on Mar 10, 2026, for Q4 FY2025 (the quarter ended Dec 31, 2025): diluted EPS of -$0.36. It usually reports 38–69 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 38–69 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Mar 10, 2026
69 days after quarter end
Q4 FY2025
ended Dec 31, 2025
—
-14
-48.2%
-0.36
-49.2%
Nov 10, 2025
41 days after quarter end
Q3 FY2025
ended Sep 30, 2025
—
-13
-227.2%
-0.32
-220.0%
Aug 7, 2025
38 days after quarter end
Q2 FY2025
ended Jun 30, 2025
—
-18
-123.0%
-0.44
-120.0%
May 8, 2025
38 days after quarter end
Q1 FY2025
ended Mar 31, 2025
—
-11
-121.2%
-0.28
-55.6%
Nov 7, 2024
38 days after quarter end
Q3 FY2024
ended Sep 30, 2024
—
-4
+84.4%
-0.10
+96.8%

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SKYE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1516551
Former names
Emerald Bioscience, Inc. (until Jan 7, 2021); Nemus Bioscience, Inc. (until Mar 14, 2019); LOAD GUARD LOGISTICS, INC. (until Oct 30, 2014); LOAD GUARD TRANSPORTATION, INC. (until Nov 7, 2012)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.